PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment

PROGRAM DESCRIPTION This activity will serve as a call to action and will bring together a cardiologist, a specialty NP, a patient advocate, and a managed care representative to address ...

PROGRAM DESCRIPTION
This activity will serve as a call to action and will bring together a cardiologist, a specialty NP, a patient advocate, and a managed care representative to address the limited access to PCSK9 inhibitors. This multidisciplinary panel will unite to discuss this issue and raise awareness in hopes of changing policies to allow more widespread access to PCSK9 inhibitors.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to:Identify high-risk individuals, including those with residual ASCVD risk such as familial hypercholesterolemia, diabetic dyslipidemia, and/or statin intolerance who would benefit for PCSK9 therapy Summarize the evidence on the risks and benefits of new and emerging hypercholesterolemia therapies to guide treatment and management decisions for patients with hypercholesterolemia who are not at goalDevelop effective strategies for patient-centered hypercholesterolemia management including patient education, medication risks/benefits, adherence, and lifestyle modificationsExplain how to implement a team-based approach to improve patient access and adherence to PCSK9 inhibitors

---

Write the first review

Resource tags